Sweden to Receive Scandinavia's First TomoTherapy System

Lund University Hospital to Offer Swedish Cancer Patients the Most
Advanced Image-Guided Radiation Therapy Treatments
MADISON, Wis.--(Business Wire)--
TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it
has extended its reach in Europe with the first TomoTherapy(R)
Hi-Art(R) treatment system set to be installed in Scandinavia, at Lund
University Hospital in Sweden.

Jef Van Dam, general manager of TomoTherapy EMEA, said,
"TomoTherapy is extremely pleased to partner with Lund University
Hospital. This marks our entry into the Swedish market with a
prestigious institution that pioneered the use of many technological
advances in Scandinavia and Europe. We look forward to delivering the
advanced Hi-Art system to continue that tradition."

Lund University Hospital conducted an extensive investigation of
all commercially available intensity-modulated radiation therapy
(IMRT) systems, including arc-based options on conventional platforms,
before making the decision to purchase the TomoTherapy Hi-Art system.

Charlott Wictor, strategic purchaser of medical equipment for the
Skane region in Sweden, championed TomoTherapy and helped the purchase
become reality: "This was a great team effort working with the Lund
medical and physics experts to bring this advanced technology to our
Swedish patients. TomoTherapy was clearly the best choice from both a
high technology and economic standpoint."

Jacob Engellau, M.D., Ph.D., head of radiation oncology at Lund
University Hospital, believes TomoTherapy will have a great impact on
patient treatments. "As a large center treating 2500 new patients
yearly, we are dependent on high up-time and clinical reliability. The
established and clinically well-implemented TomoTherapy Hi-Art was the
only system that could meet the demands of our clinic."

Tommy Knoos, Ph.D., associate professor and head of radiation
physics at Lund University Hospital, was also an important decision
maker in the process. "We think TomoTherapy is the most advanced
image-guided system for radiotherapy with an integrated functionality
for imaging and localisation of the target volume. It also produces
the most advantageous dose distributions for IMRT," according to
Knoos.

Added Engellau, "With the Hi-Art system, we see obvious clinical
advantages for treating complex radiation target volumes, multiple
targets and targets requiring a high radiation dose with close
proximity to healthy organs. Conventional 3D conformal radiation or
IMRT can treat some but not all of these case types. If the cases can
be attempted, we believe the results would be less conformal, less
accurate and with much longer treatment times than with TomoTherapy."

While TomoTherapy will be used to treat a wide array of cancers,
the clinical experts at Lund plan to focus on anal, rectal, cervical,
stomach and esophageal cancers. They will also be using the Hi-Art
system for stereotactic radiosurgery treatments and see greater
possibilities for clinical trials involving simultaneously integrated
boost (SIB) with or without dose escalation.

Lund University Hospital plans to install the TomoTherapy Hi-Art
system later this year.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the
TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation
therapy system for the treatment of a wide variety of cancers. The
Hi-Art treatment system combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with
speed and precision while reducing radiation exposure to surrounding
healthy tissue. The company's stock is traded on the NASDAQ Global
Select Market under the symbol TOMO. To learn more about TomoTherapy,
please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future events, expectations
and other similar matters, including but not limited to statements
using the terms "look forward to" or "will" constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements contained in this
press release are subject to risks and uncertainties that could cause
actual results to differ materially from those anticipated, including
but not limited to factors such as our ability to integrate acquired
assets, ability to protect intellectual property, risks of
interruption due to events beyond the company's control, and the other
risks listed from time to time in TomoTherapy's filings with the U.S.
Securities and Exchange Commission, which by this reference are
incorporated herein. These forward-looking statements represent
TomoTherapy's judgments as of the date of this press release.
TomoTherapy assumes no obligation to update or revise the
forward-looking statements in this release because of new information,
future events or otherwise.

(C)2008 TomoTherapy Incorporated. All rights
reserved. TomoTherapy, the TomoTherapy logo and Hi-Art are among
trademarks, service marks or registered trademarks of TomoTherapy
Incorporated.

TomoTherapy Incorporated
Investor Contact:
Stephen C. Hathaway
Chief Financial Officer
608.824.2800
shathaway@tomotherapy.com
or
Media Contact:
Patty Kitowski
Marketing Communications Manager
608.824.2820
pkitowski@tomotherapy.com

Copyright Business Wire 2008